Form 4: Inotiv Inc. Executive Adrian Hardy Receives Stock Options and Restricted Stock Units

Inotiv Inc.'s Chief Commercial Officer, Adrian Hardy, was granted 20,000 restricted stock units and options to purchase 20,000 shares of common stock on August 10, 2024.

Summary

• On August 10, 2024, Adrian Hardy, Chief Commercial Officer of Inotiv, Inc., received a grant of 20,000 restricted stock units.
• These restricted stock units will vest in full on June 18, 2026, contingent upon continued employment.
• Hardy also received options to purchase 20,000 shares of Inotiv's common stock at an exercise price of $1.61.
• The stock options vest over three years: 40% on June 18, 2025, 30% on June 18, 2026, and 30% on June 18, 2027, also subject to continued employment.
• Following these transactions, Hardy directly owns 33,420 shares of Inotiv's common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules for both the restricted stock units and stock options incentivize continued employment and performance.

Risks

• The value of the restricted stock units and stock options is dependent on the future performance of Inotiv's stock.
• The executive must remain employed with the company to fully vest in the granted equity.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the equity grants.

Industry Context

Equity compensation is a common practice in the biotechnology and pharmaceutical services industry to attract, retain, and incentivize key executives. The specific terms of the grant, such as vesting schedules and exercise prices, are often tailored to the individual and the company's performance goals.

Comparison to Industry Standards

• Comparing Inotiv's equity compensation practices to companies like Charles River Laboratories or Envigo (prior to its acquisition) would provide a benchmark for assessing the competitiveness of their executive compensation packages.
• Typical vesting schedules for stock options in the industry range from three to five years, with performance-based vesting becoming increasingly common.
• The size of the equity grant as a percentage of outstanding shares can also be compared to industry averages to gauge its significance.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates